University of Dundee

Biological Chemistry and Drug Discovery

Short Code: 
BCDD

Dundee scientist speaks at the Galien Innovation Forum

School of Life Science’s Professor Alessio Ciulli was amongst a selected group of world’s leading expert scientists and key opinion leaders who spoke at the Galien Forum on October 24, 2019, at the Alexandria Center in New York City.

Alessio’s panel, entitled ‘Drugging the Undruggable with Novel Approaches to Small Molecule Design’, was chaired by Pfizer’s Chief Scientific Officer and President, Worldwide Research, Development and Medical, Mikael Dolsten.

Postdoctoral Research Assistant (3 Posts)

The School of Life Sciences at the University of Dundee is a world-class academic institution with a reputation for the excellence of its research, its high quality teaching and student experience, and the strong impact of its activities outside academia. With 900 staff from over 60 countries worldwide the School provides a dynamic, multi-national, collegiate and diverse environment with state-of-the-art laboratory, technology and teaching facilities.

Protein Crystallographer/ Structural Biologist

The Drug Discovery Unit (www.drugdiscovery.dundee.ac.uk) is a dynamic and multidisciplinary group of 95 scientists with expertise in structural biology, compound handling, assay development, high-throughput screening, medicinal and computational chemistry and in vitro and in vivo pharmacokinetics. The unit is housed in a state-of-the-art building and has cutting-edge equipment and automation, including an in-house X-ray diffractometer.

DEBRA Funds 4th year towards Novel Gene Technology for Epidermolysis Bullosa

DEBRA is delighted to share that funding for a fourth year of the University of Dundee’s research into novel gene technology for treating Epidermolysis Bullosa (EB) has been agreed. £153,550 towards a total of £504,472 has been provided to enable the team lead by DEBRA Clinical Fellow, Dr Peter van den Akker (pictured), to develop two types of gene technology that can target genetic mutations caused by EB.

Two SLS entrepreneurs make Converge Challenge Final

Two academic entrepreneurs from the division of Biological Chemistry and Drug Discovery have made the final of the Converge Challenge 2019.  Andrew Woodland (In4Derm) and Michael Conneely (Ten Bio) will now go head-to-head against six other entrepreneurs leading both start-ups and spin-outs at the Converge Awards Final which takes place at the iconic V&A, Dundee later this month.  

Pages